$ENDV
ENDONOVO THERAPEUTICS, INC.

2023 Q4 Form 10-Q Financial Statement

#000149315223046444 Filed on December 29, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $1.520K $10.96K
YoY Change -86.13% 40.69%
Cost Of Revenue $827.00 $4.027K
YoY Change -79.46% 29.9%
Gross Profit $693.00 $6.933K
YoY Change -90.0% 47.83%
Gross Profit Margin 45.59% 63.26%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $161.7K $161.7K
YoY Change 0.01% 0.0%
% of Gross Profit 23337.66% 2332.61%
Operating Expenses $473.5K $503.7K
YoY Change -6.0% -27.73%
Operating Profit -$472.8K -$496.8K
YoY Change -4.83% -28.24%
Interest Expense -$285.9K -$394.8K
YoY Change -27.58% -49.96%
% of Operating Profit
Other Income/Expense, Net -$293.4K -$106.6K
YoY Change 175.26% -87.18%
Pretax Income -$766.2K -$603.4K
YoY Change 26.98% -60.4%
Income Tax
% Of Pretax Income
Net Earnings -$766.2K -$603.4K
YoY Change 26.98% -60.4%
Net Earnings / Revenue -50405.92% -5505.11%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 -$3.928K
COMMON SHARES
Basic Shares Outstanding 318.8M shares 317.9M shares 152.5M shares
Diluted Shares Outstanding 1.351B shares 153.6M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $23.14K
YoY Change -100.0% 303.84%
Cash & Equivalents $0.00 $23.14K
Short-Term Investments
Other Short-Term Assets $35.50K $0.00
YoY Change -100.0%
Inventory
Prepaid Expenses
Receivables $944.00
Other Receivables $0.00
Total Short-Term Assets $35.50K $24.08K
YoY Change 47.42% -61.5%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $780.3K $1.427M
YoY Change -45.33% -31.19%
TOTAL ASSETS
Total Short-Term Assets $35.50K $24.08K
Total Long-Term Assets $780.3K $1.427M
Total Assets $815.8K $1.451M
YoY Change -43.79% -32.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.460M $865.8K
YoY Change 68.6% 14.97%
Accrued Expenses $9.277M $7.636M
YoY Change 21.49% 21.12%
Deferred Revenue
YoY Change
Short-Term Debt $7.057M $7.240M
YoY Change -2.53% 6.92%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.70M $20.98M
YoY Change 12.96% 3.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $79.83K $79.83K
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $79.83K $79.83K
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.70M $20.98M
Total Long-Term Liabilities $79.83K $79.83K
Total Liabilities $23.78M $21.06M
YoY Change 12.91% 3.45%
SHAREHOLDERS EQUITY
Retained Earnings -$66.60M -$62.00M
YoY Change 7.42%
Common Stock $27.94K $15.92K
YoY Change 75.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$22.96M -$19.61M
YoY Change
Total Liabilities & Shareholders Equity $815.8K $1.451M
YoY Change -43.79% -32.08%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$766.2K -$603.4K
YoY Change 26.98% -60.4%
Depreciation, Depletion And Amortization $161.7K $161.7K
YoY Change 0.01% 0.0%
Cash From Operating Activities -$65.36K -$123.9K
YoY Change -47.23% -26.89%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.77K 147.0K
YoY Change -77.71% -11.76%
NET CHANGE
Cash From Operating Activities -65.36K -123.9K
Cash From Investing Activities
Cash From Financing Activities 32.77K 147.0K
Net Change In Cash -32.59K 23.14K
YoY Change -240.84% -923.49%
FREE CASH FLOW
Cash From Operating Activities -$65.36K -$123.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001528172
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
ENDV Conversion Of Preferred C Stock To Common Stock
ConversionOfPreferredCStockToCommonStock
usd
ENDV Issuance Of Common Stock To Settle Debt
IssuanceOfCommonStockToSettleDebt
usd
ENDV Conversion Of Notes To Common Stock Pursuant To Settlement Agreement
ConversionOfNotesToCommonStockPursuantToSettlementAgreement
usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
usd
CY2023Q3 ENDV Shares Issued For Conversion Of Deferred Compensation Value
SharesIssuedForConversionOfDeferredCompensationValue
usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
shares
CY2022Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
usd
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55453
dei Entity Registrant Name
EntityRegistrantName
ENDONOVO THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2552528
dei Entity Address Address Line1
EntityAddressAddressLine1
6320 Canoga Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
15th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Woodland Hills
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91367
dei City Area Code
CityAreaCode
(800)
dei Local Phone Number
LocalPhoneNumber
489-4774
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
318751597 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
35504 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15724 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
35504 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
15822 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
780260 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1265444 usd
CY2023Q3 us-gaap Assets
Assets
815764 usd
CY2022Q4 us-gaap Assets
Assets
1281266 usd
CY2023Q3 ENDV Accrued Interest Related To Notes Payable
AccruedInterestRelatedToNotesPayable
4417039 usd
CY2022Q4 ENDV Accrued Interest Related To Notes Payable
AccruedInterestRelatedToNotesPayable
3542650 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
28210 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
10587 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
5902829 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
17359064 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23696070 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33381760 usd
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
79825 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
79825 usd
CY2023Q3 us-gaap Liabilities
Liabilities
23775895 usd
CY2022Q4 us-gaap Liabilities
Liabilities
33461585 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
318751597 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
318751597 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
213227538 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
213227538 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
27940 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
21322 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43644063 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42919086 usd
CY2023Q3 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
1570 usd
CY2022Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
1570 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66630590 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75119183 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-22960131 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-32180319 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
815764 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1281266 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1520 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10960 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
134260 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13892 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
827 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
4027 usd
us-gaap Cost Of Revenue
CostOfRevenue
4823 usd
us-gaap Cost Of Revenue
CostOfRevenue
5124 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
693 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
6933 usd
us-gaap Gross Profit
GrossProfit
129437 usd
us-gaap Gross Profit
GrossProfit
8768 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
473490 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
503711 usd
us-gaap Operating Expenses
OperatingExpenses
2262833 usd
us-gaap Operating Expenses
OperatingExpenses
2790057 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-472797 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-496778 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2133396 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2781289 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-56213 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
11445466 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1903177 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
319081 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
156062 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
362894 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7481 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30879 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31999 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-208879 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-285892 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-338571 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-908141 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1012249 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-293373 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-106582 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10661388 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2761411 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-766170 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-603360 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8527992 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5542700 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-766170 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-603360 usd
us-gaap Net Income Loss
NetIncomeLoss
8527992 usd
us-gaap Net Income Loss
NetIncomeLoss
-5542700 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.002
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
298391943 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153599760 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
276355156 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122537266 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1350805130 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153599760 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1350768342 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122537266 shares
us-gaap Net Income Loss
NetIncomeLoss
8527992 usd
us-gaap Net Income Loss
NetIncomeLoss
-5542700 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
485185 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
485184 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200966 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
720562 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1281900 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
156062 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
362894 usd
ENDV Amortization Of Note Discount And Original Issue Discount
AmortizationOfNoteDiscountAndOriginalIssueDiscount
12002 usd
ENDV Amortization Of Note Discount And Original Issue Discount
AmortizationOfNoteDiscountAndOriginalIssueDiscount
90427 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
11445466 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1903177 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-9052 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7975 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
49534 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
297250 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
908141 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
921822 usd
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
283731 usd
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
464562 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-404363 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-453297 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
195000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
400000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
7500 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
9500 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
40000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
256765 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
404265 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
390500 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-98 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-62797 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
98 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
85936 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23139 usd
us-gaap Notes Issued1
NotesIssued1
109000 usd
us-gaap Notes Issued1
NotesIssued1
339000 usd
ENDV Conversion Of Preferred C Stock To Common Stock
ConversionOfPreferredCStockToCommonStock
500 usd
ENDV Issuance Of Common Stock To Settle Debt
IssuanceOfCommonStockToSettleDebt
45000 usd
ENDV Debt Discount From Issuance Of Debt
DebtDiscountFromIssuanceOfDebt
32875 usd
ENDV Debt Discount From Issuance Of Debt
DebtDiscountFromIssuanceOfDebt
44098 usd
ENDV Conversion Of Notes To Common Stock Pursuant To Settlement Agreement
ConversionOfNotesToCommonStockPursuantToSettlementAgreement
159419 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-32180319 usd
CY2023Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
109000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
24870 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
67089 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
172950 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
207000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
7230502 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-24368908 usd
CY2023Q2 ENDV Shares Issued For Conversion Of Deferred Compensation Value
SharesIssuedForConversionOfDeferredCompensationValue
24338 usd
CY2023Q2 ENDV Stock Issued During Period Value Connection With Promissory Notes
StockIssuedDuringPeriodValueConnectionWithPromissoryNotes
11125 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
6025 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
16000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
2063660 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-22411889 usd
CY2023Q3 ENDV Stock Issued During Period Value Connection With Promissory Notes
StockIssuedDuringPeriodValueConnectionWithPromissoryNotes
3250 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
4550 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-766170 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-22960131 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-15774324 usd
CY2022Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
88800 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
46147 usd
CY2022Q1 ENDV Stock Issued During Period Value Connection With Promissory Notes
StockIssuedDuringPeriodValueConnectionWithPromissoryNotes
15750 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2413209 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-18036836 usd
CY2022Q2 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
115200 usd
CY2022Q2 ENDV Stock Issued During Period Value Connection With Promissory Notes
StockIssuedDuringPeriodValueConnectionWithPromissoryNotes
5733 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1281900 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2526131 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-19160134 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-19160134 usd
CY2022Q3 ENDV Stock Issued During Period Value Connection With Promissory Notes
StockIssuedDuringPeriodValueConnectionWithPromissoryNotes
22615 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
135000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-603360 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-603360 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-19605879 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-19605879 usd
CY2023Q3 us-gaap Cash
Cash
0 usd
CY2023Q3 ENDV Working Capital Deficiency
WorkingCapitalDeficiency
23100000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-400000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66600000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
500000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_zcmqWvWdAtz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zcT6S6Y9kHGc">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
8857992 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5542700 usd
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-10823217 usd
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-2295225 usd
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-5542700 usd
ENDV Weighted Average Number Of Diluted Shares Outstanding Gross
WeightedAverageNumberOfDilutedSharesOutstandingGross
276355156 shares
ENDV Weighted Average Number Of Diluted Shares Outstanding Gross
WeightedAverageNumberOfDilutedSharesOutstandingGross
55303026 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1074413187 shares
ENDV Common Stock And Common Stock Equivalents Used For Diluted Income Per Share
CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare
1350768342 shares
ENDV Common Stock And Common Stock Equivalents Used For Diluted Income Per Share
CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare
55303026 shares
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-766170 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-603360 usd
CY2023Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
285892 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-480278 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-603360 usd
CY2023Q3 ENDV Weighted Average Number Of Diluted Shares Outstanding Gross
WeightedAverageNumberOfDilutedSharesOutstandingGross
298391943 shares
CY2022Q3 ENDV Weighted Average Number Of Diluted Shares Outstanding Gross
WeightedAverageNumberOfDilutedSharesOutstandingGross
153599760 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1074413187 shares
CY2023Q3 ENDV Common Stock And Common Stock Equivalents Used For Diluted Income Per Share
CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare
1372805130 shares
CY2022Q3 ENDV Common Stock And Common Stock Equivalents Used For Diluted Income Per Share
CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare
153599760 shares
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1520 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10960 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
134260 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13892 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1281900 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
CY2023Q3 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
4500000 usd
CY2022Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
4500000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3719740 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3234556 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
780260 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1265444 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
485184 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
646192 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
134068 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
780260 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
7163832 usd
CY2021Q4 us-gaap Notes Payable
NotesPayable
7256930 usd
ENDV Notes Payable Issued
NotesPayableIssued
195000 usd
CY2022 ENDV Notes Payable Issued
NotesPayableIssued
465000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
40000 usd
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
14000 usd
ENDV Settlements On Note Payable
SettlementsOnNotePayable
-133650 usd
CY2022 ENDV Settlements On Note Payable
SettlementsOnNotePayable
-163826 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
100000 usd
CY2022 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
380272 usd
CY2023Q3 us-gaap Notes Payable
NotesPayable
7085182 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
7163832 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
28210 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
10587 usd
CY2023Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
7056972 usd
CY2022Q4 us-gaap Notes And Loans Payable
NotesAndLoansPayable
7153245 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
36000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P2Y6M
CY2023Q3 ENDV Long Term Debt Past Maturity
LongTermDebtPastMaturity
6875182 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
210000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
7085182 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
100000 usd
us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
9000 usd
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
10900000 shares
us-gaap Repayments Of Debt
RepaymentsOfDebt
20000 usd
CY2023Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1000000 shares
ENDV Extension Fee Payable
ExtensionFeePayable
2500 usd
ENDV Notes Payable Issued
NotesPayableIssued
195000 usd
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1440000 usd
CY2023Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
338403 usd
us-gaap Debt Instrument Description
DebtInstrumentDescription
the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares.
CY2023Q3 ENDV Good Provision Value
GoodProvisionValue
250000 usd
ENDV Certain Fixed Percentage Of Cash Premium
CertainFixedPercentageOfCashPremium
certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium.
CY2022Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
124900 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
214100 usd
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
16950000 shares
ENDV Certain Fixed Percentage Of Cash Premium
CertainFixedPercentageOfCashPremium
Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% or 18% premium upon cash redemption by the Company.
CY2022Q3 ENDV Prepayment Penalty
PrepaymentPenalty
243000 usd
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
43800000 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
720562 usd
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
62250000 shares
CY2023Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
5902829 usd
CY2023Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
5902829 usd

Files In Submission

Name View Source Status
endv-20230930_lab.xml Edgar Link unprocessable
endv-20230930_pre.xml Edgar Link unprocessable
endv-20230930_def.xml Edgar Link unprocessable
endv-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001493152-23-046444-index-headers.html Edgar Link pending
0001493152-23-046444-index.html Edgar Link pending
0001493152-23-046444.txt Edgar Link pending
0001493152-23-046444-xbrl.zip Edgar Link pending
endv-20230930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending